Share Price and Basic Stock Data
Last Updated: January 28, 2026, 12:01 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Terce Laboratories Ltd operates within the pharmaceuticals industry, with a current share price of ₹43.5 and a market capitalization of ₹32.3 Cr. The company’s revenue from operations has shown a steady upward trend, standing at ₹46.78 Cr for the fiscal year ending March 2023, and anticipated to rise to ₹50.20 Cr by March 2025. Quarterly sales have fluctuated, with the latest reported figure for September 2023 at ₹12.03 Cr, following a peak of ₹12.89 Cr in March 2023. This indicates a recovery from a dip to ₹10.72 Cr in June 2023. The trailing twelve-month revenue is ₹48.78 Cr, reflecting a consistent performance in sales despite periodic fluctuations. Overall, Gujarat Terce has demonstrated resilience in revenue generation, supported by a diverse product portfolio and market presence, although it continues to navigate challenges in operational efficiency.
Profitability and Efficiency Metrics
The profitability metrics for Gujarat Terce Laboratories reveal a mixed performance. The operating profit margin (OPM) stood at 14.62% as of September 2025, showcasing a significant recovery from negative margins earlier in the timeline, with the highest margin recorded at 14.62% in the latest quarter. However, net profit figures have been volatile, with a reported net profit of -₹1.02 Cr for the trailing twelve months, contrasting sharply with previous periods where profits were recorded, such as ₹0.33 Cr in September 2023. The company’s return on equity (ROE) is reported at 14.6%, indicating effective use of shareholder capital, while the return on capital employed (ROCE) is notably high at 41.4%. These figures suggest that while Gujarat Terce faces challenges in net profitability, its operational efficiency and capital utilization remain strong, positioning it favorably against industry norms.
Balance Sheet Strength and Financial Ratios
Gujarat Terce Laboratories maintains a balance sheet that reflects cautious financial management. Total borrowings are reported at ₹0.60 Cr, indicating low leverage, particularly when compared to total liabilities of ₹24.43 Cr as of September 2025. The company has a current ratio of 0.95, slightly below the ideal benchmark of 1, suggesting potential liquidity concerns. The interest coverage ratio (ICR) is robust at 10.09x, indicating that the company can comfortably meet its interest obligations. However, the book value per share has declined to ₹8.73, down from ₹9.58 a year earlier, reflecting a reduction in net worth. Furthermore, the price-to-book value (P/BV) ratio stands at 7.00x, suggesting that the stock is trading at a premium relative to its book value, which could deter value-oriented investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gujarat Terce Laboratories indicates a significant public ownership of 62.97%. Promoter holding stands at 37.03%, which has shown a slight increase over recent quarters, reflecting growing confidence from the management. The number of shareholders has seen a gradual increase, reaching 13,812 by September 2025, suggesting a growing interest in the stock despite its recent profitability challenges. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could indicate a lack of institutional confidence, which may impact long-term stock performance. However, the steady promoter stake and increasing public participation may provide a buffer against volatility, fostering a more engaged retail investor base.
Outlook, Risks, and Final Insight
Looking ahead, Gujarat Terce Laboratories faces both opportunities and challenges. On the positive side, the company’s high ROCE of 41.4% and improving operating margins signal potential for future profitability as operational efficiencies are enhanced. However, risks remain, particularly in the form of fluctuating net profits and liquidity concerns, as indicated by a current ratio below 1. The company must focus on stabilizing its earnings and improving cash flow management to attract institutional investors. Additionally, maintaining a lean balance sheet with minimal debt will be crucial for navigating market uncertainties. Overall, while Gujarat Terce has strengths in operational efficiency and a solid promoter holding, addressing profitability and liquidity challenges will be essential for sustainable growth and investor confidence moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 97.8 | 197/84.3 | 27.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,486 Cr. | 320 | 479/192 | 72.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.6 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 66.4 Cr. | 45.4 | 45.6/17.0 | 158 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,496.45 Cr | 1,084.99 | 47.48 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.58 | 11.90 | 12.89 | 10.72 | 12.03 | 13.02 | 12.21 | 11.89 | 13.30 | 12.68 | 12.32 | 10.85 | 12.93 |
| Expenses | 12.98 | 11.77 | 13.08 | 11.85 | 11.48 | 12.18 | 11.20 | 11.81 | 11.64 | 11.60 | 11.27 | 10.86 | 11.04 |
| Operating Profit | -0.40 | 0.13 | -0.19 | -1.13 | 0.55 | 0.84 | 1.01 | 0.08 | 1.66 | 1.08 | 1.05 | -0.01 | 1.89 |
| OPM % | -3.18% | 1.09% | -1.47% | -10.54% | 4.57% | 6.45% | 8.27% | 0.67% | 12.48% | 8.52% | 8.52% | -0.09% | 14.62% |
| Other Income | 0.10 | 0.08 | 0.10 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | 0.09 | 0.09 | 0.06 |
| Interest | 0.22 | 0.14 | 0.17 | 0.17 | 0.20 | 0.16 | 0.15 | 0.13 | 0.13 | 0.08 | 0.07 | 0.05 | 0.07 |
| Depreciation | 0.07 | 0.07 | 0.16 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 |
| Profit before tax | -0.59 | -0.00 | -0.42 | -1.31 | 0.34 | 0.67 | 0.85 | -0.07 | 1.52 | 0.97 | 0.97 | -0.07 | 1.78 |
| Tax % | -0.00% | -290.48% | -0.00% | -0.00% | -0.00% | 35.29% | 14.29% | 1.97% | -3.09% | 449.48% | -42.86% | 21.35% | |
| Net Profit | -0.59 | -0.00 | 0.80 | -1.31 | 0.33 | 0.67 | 0.54 | -0.08 | 1.48 | 1.01 | -3.39 | -0.04 | 1.40 |
| EPS in Rs | -0.80 | -0.00 | 1.08 | -1.77 | 0.44 | 0.90 | 0.73 | -0.11 | 1.99 | 1.36 | -4.57 | -0.05 | 1.89 |
Last Updated: January 8, 2026, 3:03 am
Below is a detailed analysis of the quarterly data for Gujarat Terce Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 12.93 Cr.. The value appears strong and on an upward trend. It has increased from 10.85 Cr. (Jun 2025) to 12.93 Cr., marking an increase of 2.08 Cr..
- For Expenses, as of Sep 2025, the value is 11.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.86 Cr. (Jun 2025) to 11.04 Cr., marking an increase of 0.18 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.89 Cr.. The value appears strong and on an upward trend. It has increased from -0.01 Cr. (Jun 2025) to 1.89 Cr., marking an increase of 1.90 Cr..
- For OPM %, as of Sep 2025, the value is 14.62%. The value appears strong and on an upward trend. It has increased from -0.09% (Jun 2025) to 14.62%, marking an increase of 14.71%.
- For Other Income, as of Sep 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Jun 2025) to 0.06 Cr., marking a decrease of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.05 Cr. (Jun 2025) to 0.07 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.10 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.78 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Jun 2025) to 1.78 Cr., marking an increase of 1.85 Cr..
- For Tax %, as of Sep 2025, the value is 21.35%. The value appears to be increasing, which may not be favorable. It has increased from -42.86% (Jun 2025) to 21.35%, marking an increase of 64.21%.
- For Net Profit, as of Sep 2025, the value is 1.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to 1.40 Cr., marking an increase of 1.44 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.89. The value appears strong and on an upward trend. It has increased from -0.05 (Jun 2025) to 1.89, marking an increase of 1.94.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.84 | 26.48 | 25.00 | 25.29 | 29.01 | 31.03 | 37.54 | 25.18 | 40.13 | 46.78 | 47.92 | 50.20 | 48.78 |
| Expenses | 27.89 | 25.70 | 24.84 | 25.21 | 28.68 | 30.54 | 36.86 | 27.77 | 39.02 | 48.94 | 46.65 | 46.31 | 44.77 |
| Operating Profit | 0.95 | 0.78 | 0.16 | 0.08 | 0.33 | 0.49 | 0.68 | -2.59 | 1.11 | -2.16 | 1.27 | 3.89 | 4.01 |
| OPM % | 3.29% | 2.95% | 0.64% | 0.32% | 1.14% | 1.58% | 1.81% | -10.29% | 2.77% | -4.62% | 2.65% | 7.75% | 8.22% |
| Other Income | 0.13 | 0.08 | 0.19 | 0.44 | 0.41 | 0.32 | 0.29 | 0.62 | 0.31 | 0.35 | 0.32 | 0.31 | 0.31 |
| Interest | 0.41 | 0.41 | 0.38 | 0.31 | 0.23 | 0.25 | 0.29 | 0.39 | 0.40 | 0.72 | 0.68 | 0.42 | 0.27 |
| Depreciation | 0.33 | 0.16 | 0.19 | 0.19 | 0.19 | 0.21 | 0.24 | 0.18 | 0.28 | 0.36 | 0.37 | 0.38 | 0.40 |
| Profit before tax | 0.34 | 0.29 | -0.22 | 0.02 | 0.32 | 0.35 | 0.44 | -2.54 | 0.74 | -2.89 | 0.54 | 3.40 | 3.65 |
| Tax % | 29.41% | 72.41% | 209.09% | 150.00% | 15.62% | -25.71% | 36.36% | -0.39% | -17.57% | -42.21% | 55.56% | 128.53% | |
| Net Profit | 0.24 | 0.09 | -0.67 | -0.01 | 0.27 | 0.43 | 0.28 | -2.52 | 0.87 | -1.67 | 0.24 | -0.98 | -1.02 |
| EPS in Rs | 0.32 | 0.12 | -0.90 | -0.01 | 0.36 | 0.58 | 0.38 | -3.40 | 1.17 | -2.25 | 0.32 | -1.32 | -1.37 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -62.50% | -844.44% | 98.51% | 2800.00% | 59.26% | -34.88% | -1000.00% | 134.52% | -291.95% | 114.37% | -508.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -781.94% | 942.95% | 2701.49% | -2740.74% | -94.14% | -965.12% | 1134.52% | -426.48% | 406.33% | -622.70% |
Gujarat Terce Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 3:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| Reserves | 3.52 | 3.61 | 2.94 | 2.64 | 2.98 | 3.41 | 3.69 | 0.24 | 1.11 | -0.56 | -0.31 | -0.94 | 0.42 |
| Borrowings | 8.74 | 8.21 | 7.13 | 7.00 | 0.37 | 0.68 | 2.60 | 4.74 | 6.67 | 7.27 | 3.87 | 0.94 | 0.60 |
| Other Liabilities | 6.24 | 7.06 | 6.98 | 6.59 | 8.69 | 7.94 | 8.80 | 9.47 | 12.19 | 14.39 | 12.29 | 15.41 | 15.99 |
| Total Liabilities | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.43 |
| Fixed Assets | 6.13 | 6.48 | 6.34 | 6.17 | 1.88 | 2.06 | 2.29 | 2.45 | 4.29 | 3.99 | 3.69 | 3.65 | 3.47 |
| CWIP | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.30 | 0.30 | 0.24 | 0.27 | 0.29 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.52 | 2.62 |
| Other Assets | 19.77 | 19.52 | 17.83 | 17.24 | 17.31 | 17.10 | 19.95 | 19.15 | 22.83 | 24.26 | 19.31 | 18.66 | 18.34 |
| Total Assets | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 | 24.43 |
Below is a detailed analysis of the balance sheet data for Gujarat Terce Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 7.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.42 Cr..
- For Reserves, as of Sep 2025, the value is 0.42 Cr.. The value appears strong and on an upward trend. It has increased from -0.94 Cr. (Mar 2025) to 0.42 Cr., marking an increase of 1.36 Cr..
- For Borrowings, as of Sep 2025, the value is 0.60 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 0.94 Cr. (Mar 2025) to 0.60 Cr., marking a decrease of 0.34 Cr..
- For Other Liabilities, as of Sep 2025, the value is 15.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.41 Cr. (Mar 2025) to 15.99 Cr., marking an increase of 0.58 Cr..
- For Total Liabilities, as of Sep 2025, the value is 24.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.83 Cr. (Mar 2025) to 24.43 Cr., marking an increase of 1.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.65 Cr. (Mar 2025) to 3.47 Cr., marking a decrease of 0.18 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.62 Cr.. The value appears strong and on an upward trend. It has increased from 0.52 Cr. (Mar 2025) to 2.62 Cr., marking an increase of 2.10 Cr..
- For Other Assets, as of Sep 2025, the value is 18.34 Cr.. The value appears to be declining and may need further review. It has decreased from 18.66 Cr. (Mar 2025) to 18.34 Cr., marking a decrease of 0.32 Cr..
- For Total Assets, as of Sep 2025, the value is 24.43 Cr.. The value appears strong and on an upward trend. It has increased from 22.83 Cr. (Mar 2025) to 24.43 Cr., marking an increase of 1.60 Cr..
However, the Borrowings (0.60 Cr.) are higher than the Reserves (0.42 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.79 | -7.43 | -6.97 | -6.92 | -0.04 | -0.19 | -1.92 | -7.33 | -5.56 | -9.43 | -2.60 | 2.95 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116.56 | 126.81 | 123.81 | 114.31 | 57.62 | 53.29 | 68.16 | 74.94 | 49.75 | 62.34 | 43.11 | 36.86 |
| Inventory Days | 112.27 | 142.73 | 162.86 | 150.01 | 126.33 | 114.69 | 90.00 | 136.65 | 153.90 | 83.56 | 81.09 | 71.03 |
| Days Payable | 58.79 | 88.41 | 92.30 | 59.70 | 110.67 | 85.26 | 83.44 | 104.13 | 96.22 | 110.35 | 97.39 | 69.87 |
| Cash Conversion Cycle | 170.04 | 181.14 | 194.37 | 204.61 | 73.29 | 82.72 | 74.72 | 107.46 | 107.43 | 35.56 | 26.81 | 38.02 |
| Working Capital Days | 93.78 | 97.04 | 110.52 | 86.74 | 20.89 | 27.88 | 25.18 | -14.06 | 6.82 | -20.21 | -7.69 | -13.89 |
| ROCE % | 3.80% | 3.39% | 0.87% | 1.91% | 2.95% | 5.39% | 5.79% | -15.09% | 8.26% | -14.80% | 9.72% | 41.41% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -1.32 | 0.33 | -2.25 | 1.18 | -3.40 |
| Diluted EPS (Rs.) | -1.32 | 0.33 | -2.25 | 1.18 | -3.40 |
| Cash EPS (Rs.) | -0.80 | 0.82 | -1.76 | 1.55 | -3.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.73 | 9.58 | 9.25 | 11.50 | 10.32 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.73 | 9.58 | 9.25 | 11.50 | 10.32 |
| Revenue From Operations / Share (Rs.) | 67.64 | 64.65 | 63.05 | 54.09 | 33.93 |
| PBDIT / Share (Rs.) | 5.65 | 2.14 | -2.44 | 1.92 | -2.65 |
| PBIT / Share (Rs.) | 5.13 | 1.64 | -2.93 | 1.55 | -2.89 |
| PBT / Share (Rs.) | 4.57 | 0.73 | -3.90 | 1.01 | -3.41 |
| Net Profit / Share (Rs.) | -1.32 | 0.32 | -2.25 | 1.18 | -3.40 |
| PBDIT Margin (%) | 8.34 | 3.30 | -3.86 | 3.54 | -7.80 |
| PBIT Margin (%) | 7.58 | 2.54 | -4.64 | 2.85 | -8.50 |
| PBT Margin (%) | 6.75 | 1.13 | -6.18 | 1.86 | -10.05 |
| Net Profit Margin (%) | -1.94 | 0.50 | -3.57 | 2.17 | -10.00 |
| Return on Networth / Equity (%) | -15.10 | 3.42 | -24.35 | 10.22 | -32.89 |
| Return on Capital Employeed (%) | 37.36 | 10.95 | -18.22 | 8.09 | -21.08 |
| Return On Assets (%) | -4.28 | 1.04 | -5.85 | 3.18 | -11.55 |
| Long Term Debt / Equity (X) | 0.04 | 0.13 | 0.21 | 0.26 | 0.05 |
| Total Debt / Equity (X) | 0.14 | 0.54 | 1.06 | 0.78 | 0.59 |
| Asset Turnover Ratio (%) | 2.18 | 1.85 | 1.67 | 1.63 | 1.14 |
| Current Ratio (X) | 0.95 | 0.92 | 0.96 | 1.17 | 1.03 |
| Quick Ratio (X) | 0.66 | 0.59 | 0.69 | 0.68 | 0.70 |
| Inventory Turnover Ratio (X) | 13.10 | 1.80 | 1.11 | 1.40 | 0.95 |
| Interest Coverage Ratio (X) | 10.09 | 2.35 | -2.51 | 3.55 | -5.05 |
| Interest Coverage Ratio (Post Tax) (X) | -1.36 | 1.36 | -1.32 | 3.18 | -5.47 |
| Enterprise Value (Cr.) | 45.53 | 43.07 | 17.60 | 26.07 | 8.45 |
| EV / Net Operating Revenue (X) | 0.90 | 0.89 | 0.37 | 0.64 | 0.33 |
| EV / EBITDA (X) | 10.87 | 27.12 | -9.74 | 18.31 | -4.30 |
| MarketCap / Net Operating Revenue (X) | 0.90 | 0.81 | 0.26 | 0.48 | 0.20 |
| Price / BV (X) | 7.00 | 5.53 | 1.80 | 2.27 | 0.67 |
| Price / Net Operating Revenue (X) | 0.90 | 0.81 | 0.26 | 0.48 | 0.20 |
| EarningsYield | -0.02 | 0.01 | -0.13 | 0.04 | -0.48 |
After reviewing the key financial ratios for Gujarat Terce Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 3. It has decreased from 0.82 (Mar 24) to -0.80, marking a decrease of 1.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 67.64. It has increased from 64.65 (Mar 24) to 67.64, marking an increase of 2.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 2.14 (Mar 24) to 5.65, marking an increase of 3.51.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.13. This value is within the healthy range. It has increased from 1.64 (Mar 24) to 5.13, marking an increase of 3.49.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.57, marking an increase of 3.84.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 2. It has decreased from 0.32 (Mar 24) to -1.32, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 8.34. This value is below the healthy minimum of 10. It has increased from 3.30 (Mar 24) to 8.34, marking an increase of 5.04.
- For PBIT Margin (%), as of Mar 25, the value is 7.58. This value is below the healthy minimum of 10. It has increased from 2.54 (Mar 24) to 7.58, marking an increase of 5.04.
- For PBT Margin (%), as of Mar 25, the value is 6.75. This value is below the healthy minimum of 10. It has increased from 1.13 (Mar 24) to 6.75, marking an increase of 5.62.
- For Net Profit Margin (%), as of Mar 25, the value is -1.94. This value is below the healthy minimum of 5. It has decreased from 0.50 (Mar 24) to -1.94, marking a decrease of 2.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.10. This value is below the healthy minimum of 15. It has decreased from 3.42 (Mar 24) to -15.10, marking a decrease of 18.52.
- For Return on Capital Employeed (%), as of Mar 25, the value is 37.36. This value is within the healthy range. It has increased from 10.95 (Mar 24) to 37.36, marking an increase of 26.41.
- For Return On Assets (%), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 5. It has decreased from 1.04 (Mar 24) to -4.28, marking a decrease of 5.32.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.04, marking a decrease of 0.09.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.14. This value is within the healthy range. It has decreased from 0.54 (Mar 24) to 0.14, marking a decrease of 0.40.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.18. It has increased from 1.85 (Mar 24) to 2.18, marking an increase of 0.33.
- For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has increased from 0.92 (Mar 24) to 0.95, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 24) to 0.66, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 13.10. This value exceeds the healthy maximum of 8. It has increased from 1.80 (Mar 24) to 13.10, marking an increase of 11.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 10.09, marking an increase of 7.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 3. It has decreased from 1.36 (Mar 24) to -1.36, marking a decrease of 2.72.
- For Enterprise Value (Cr.), as of Mar 25, the value is 45.53. It has increased from 43.07 (Mar 24) to 45.53, marking an increase of 2.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.90, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 10.87. This value is within the healthy range. It has decreased from 27.12 (Mar 24) to 10.87, marking a decrease of 16.25.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 7.00. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 7.00, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Terce Laboratories Ltd:
- Net Profit Margin: -1.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 37.36% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 47.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 122/2, Ravi Estate, Gandhinagar District Gujarat 382729 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Natwarbhai P Prajapati | Chairman |
| Mr. Amrutbhai P Prajapati | Whole Time Director |
| Mr. Aalap Prajapat | Managing Director & CEO |
| Mrs. Chhayaben A Shah | Independent Director |
| Mr. Viplav S Khamar | Independent Director |
| Mr. Surendra Kumar Sharma | Independent Director |
| Mr. Navinchandra Patel | Independent Director |
FAQ
What is the intrinsic value of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd's intrinsic value (as of 28 January 2026) is ₹14.71 which is 66.26% lower the current market price of ₹43.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹32.3 Cr. market cap, FY2025-2026 high/low of ₹82.8/37.2, reserves of ₹0.42 Cr, and liabilities of ₹24.43 Cr.
What is the Market Cap of Gujarat Terce Laboratories Ltd?
The Market Cap of Gujarat Terce Laboratories Ltd is 32.3 Cr..
What is the current Stock Price of Gujarat Terce Laboratories Ltd as on 28 January 2026?
The current stock price of Gujarat Terce Laboratories Ltd as on 28 January 2026 is ₹43.6.
What is the High / Low of Gujarat Terce Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Terce Laboratories Ltd stocks is ₹82.8/37.2.
What is the Stock P/E of Gujarat Terce Laboratories Ltd?
The Stock P/E of Gujarat Terce Laboratories Ltd is .
What is the Book Value of Gujarat Terce Laboratories Ltd?
The Book Value of Gujarat Terce Laboratories Ltd is 10.6.
What is the Dividend Yield of Gujarat Terce Laboratories Ltd?
The Dividend Yield of Gujarat Terce Laboratories Ltd is 0.00 %.
What is the ROCE of Gujarat Terce Laboratories Ltd?
The ROCE of Gujarat Terce Laboratories Ltd is 41.4 %.
What is the ROE of Gujarat Terce Laboratories Ltd?
The ROE of Gujarat Terce Laboratories Ltd is 14.6 %.
What is the Face Value of Gujarat Terce Laboratories Ltd?
The Face Value of Gujarat Terce Laboratories Ltd is 10.0.